Pfizer Inc. Fourth Quarter Earnings Preview

S&P 500 (NYSE:SPY) component Pfizer, Inc. (NYSE:PFE) will unveil its latest earnings on Tuesday, January 31, 2012. Pfizer is a global pharmaceutical company which develops and manufactures prescription medications for humans and animals.

Pfizer, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 47 cents per share, no change from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 50 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 47 cents during the last month. Analysts are projecting profit to rise by 2.2% versus last year to $2.28.

Past Earnings Performance: Last quarter, the company beat estimates by 6 cents, coming in at net income of 62 cents a share versus the estimate of profit of 56 cents a share. It marked the fourth straight quarter of beating estimates.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: Analysts are projecting a decline of 5.5% in revenue from the year-earlier quarter to $16.59 billion.

Analyst Ratings: Analysts are bullish on this stock with 15 analysts rating it as a buy, none rating it as a sell and two rating it as a hold.

A Look Back: In the third quarter, profit rose more than fourfold to $3.74 billion (48 cents a share) from $866 million (11 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 6.3% to $17.19 billion from $16.17 billion.

Key Stats:

The company has seen net income rise in three straight quarters. Net income rose 5.5% in the second quarter and 9.7% in the first quarter.

A year-over-year revenue increase in the third quarter snapped a streak of two consecutive quarters of revenue declines. Revenue fell 2% in the second quarter and 1.5% in the first quarter.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Eli Lilly & Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Mylan Inc. (NASDAQ:MYL), Amgen, Inc. (NASDAQ:AMGN), and Sanofi-Aventis SA (NYSE:SNY).

Stock Price Performance: During November 25, 2011 to January 25, 2012, the stock price had risen $3.27 (17.7%) from $18.45 to $21.72. The stock price saw one of its best stretches over the last year between April 21, 2011 and May 2, 2011 when shares rose for seven-straight days, rising 6.2% (+$1.19) over that span. It saw one of its worst periods between July 6, 2011 and July 18, 2011 when shares fell for nine-straight days, falling 5.5% (-$1.12) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at